1&h=220242700&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmedtronic&a=LinkedIn&a=LinkedIn).**Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.****Contacts:**Gary JeanfaivrePublic Relations+1-203-556-0777Ryan WeispfenningInvestor Relations+1-612- 839-4549SOURCE Medtronic plc![](https://rt.prnewswire.com/rt.gif? NewsIte ...

Core Insights - Medtronic plc has initiated the U.S. commercial rollout of the MiniMed 780G system integrated with Abbott's Instinct sensor, marking a significant advancement in diabetes management technology [1][8] - The MiniMed 780G system has received multiple regulatory approvals, including CE Mark for expanded indications and U.S. FDA approval for adults with type 2 diabetes, enhancing its market potential [2][4] - The global diabetes devices market is valued at $30.31 billion in 2023 and is expected to grow at a CAGR of 7.5% through 2030, driven by increasing diabetes prevalence and technological advancements [9] Company Developments - The MiniMed 780G system automatically adjusts insulin every five minutes based on real-time glucose readings, simplifying diabetes management [4][5] - The integration of Abbott's Instinct sensor, which features advanced continuous glucose monitoring technology, enhances the MiniMed 780G's capabilities [4][6] - Medtronic's Diabetes business is experiencing a strong innovation cycle, with recent product launches expanding its sensor portfolio [2][6] Financial Performance - Medtronic's market capitalization stands at $132.48 billion, with fiscal 2026 EPS expected to grow by 2.9% over 2025 [3] - The company reported worldwide revenues of $8.961 billion for fiscal 2026 second-quarter, reflecting a 6.6% year-over-year increase, with the Diabetes business growing particularly strong in international markets [10] - Year-to-date, Medtronic's shares have increased by 27.8%, outperforming the industry growth of 3.9% [11]

Continue Reading MiniMedâ"¢ 780G system with Instinct sensor now commercially available. The Instinct sensor is based on Abbott's most advanced CGM technology, featuring the world's smallest, thinnest, most discreet sensor and offers a wear time of up to 15 days. When paired with the MiniMedâ"¢ 780G system, the Instinct sensor provides real-time glucose readings which the system uses to automate insulin adjustments every five minutes, helping people with diabetes spend less time managing their condition and ...

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

Core Insights - Medtronic plc (NYSE:MDT) has been recognized as one of the 15 Best Boring Dividend Stocks to Buy, indicating its stable dividend performance and investment appeal [1] - Barclays has raised its price target for Medtronic to $111 from $109, maintaining an Overweight rating after the company reported strong earnings that exceeded expectations [2] - For Q2 of fiscal 2026, Medtronic reported sales of $9 billion, a 6.6% increase year-over-year, with adjusted earnings per share rising 8% to $1.36, surpassing analyst projections [3] Financial Performance - Medtronic's cardiovascular segment was a significant contributor to its strong results, generating $3.4 billion in revenue, which is a 10.8% increase year-over-year, marking the fastest growth rate for this segment in over a decade [4] - The overall performance reflects a solid standing for Medtronic as a leader in the medical device industry, with both revenue and EPS exceeding the company's own guidance [3] Innovation and Product Development - Medtronic is recognized for its continuous innovation, consistently launching new products and maintaining a diverse portfolio of hundreds of medical devices, which supports steady revenue and earnings growth [5] - The company's focus on developing medical devices and therapies aims to treat various health conditions, thereby reducing pain and extending life [5]

Core Insights - Long-term investment strategies focusing on companies with in-demand products can yield favorable results, particularly in the healthcare sector, though current industry leaders may not always be the best choices [1] Surgical Robotics - Intuitive Surgical expanded its installed base of surgical robots by 13% in Q3 2025, with surgeries performed increasing by 20%, indicating strong demand [3] - Approximately 75% of Intuitive Surgical's revenue comes from parts and services for its robots, presenting a significant growth opportunity, although its P/E ratio is high at 74 [3][5] - Medtronic's P/E ratio is significantly lower at 28, and the company is working to catch up in the surgical robotics market, which could enhance its growth prospects [5][6] Pharmaceutical Sector - Eli Lilly's GLP-1 drugs contributed over 50% of its sales in Q3 2025, leading to a high P/E ratio of 53, but future success is uncertain [7] - Pfizer's P/E ratio of around 15 reflects low investor expectations, partly due to an impending patent cliff and a weak pipeline, despite a high dividend yield of 6.8% [8][10] - Pfizer's acquisition of Metsera, a competitor with a promising drug pipeline, indicates proactive measures to enhance its market position [10] Dividend Stocks - Medtronic has a strong track record with 48 consecutive annual dividend increases, making it an attractive long-term investment option [6] - Johnson & Johnson, known as a Dividend King with over five decades of annual dividend increases, offers a 2.5% dividend yield and operates in both pharmaceutical and medical device sectors [13][14] - J&J's P/E ratio of 20 is moderate compared to other companies, suggesting a more stable investment with less volatility [14] Investment Strategy - While Intuitive Surgical and Eli Lilly are currently popular, their high valuations may not be sustainable long-term, making Medtronic and Pfizer more attractive options for buy-and-hold investors [15][16]

Group 1 - The article highlights a series of corruption cases involving pharmaceutical companies and agents bribing hospital personnel, with the National Healthcare Security Administration (NHSA) stating that such bribery disrupts normal medical practices and shifts sales from clinical value to high rebates and kickbacks [2][6] - Multiple companies, including Medtronic and A-share listed companies like Qianhong Pharmaceutical and Dezhan Health, have been named in recent court rulings related to these corruption cases [2][5] - Specific cases include Medtronic's agents bribing hospital officials with kickbacks of 5,000 yuan per stent and varying amounts for balloons, leading to a total bribe exceeding 14 million yuan [3][4] Group 2 - The case involving Qianhong Pharmaceutical and Dezhan Health reveals that from January 2013 to May 2019, a hospital's pharmacy director received over 116,000 yuan in bribes from various pharmaceutical representatives, including 4,100 yuan from Qianhong Pharmaceutical [5] - The NHSA has established a credit evaluation system for pricing and procurement to address the inflated prices revealed by these cases, aiming to protect patients and healthcare funds [6]

Core Insights - The National Healthcare Security Administration (NHSA) has recently exposed multiple corruption and illegal cases involving various pharmaceutical companies, including Medtronic, Qianhong Pharmaceutical, and Dezhan Health, highlighting systemic issues in the medical procurement process [1][4]. Group 1: Corruption Cases - Medtronic's agents were found to have bribed hospital officials to promote the sale of stents and balloons, with kickbacks of 5,000 RMB per stent and varying amounts for balloons based on their price [2][3]. - The total amount of bribes received by a hospital vice president from Medtronic's agents was reported to be over 6.74 million RMB from 2014 to 2018 [2]. - In a separate case, Qianhong Pharmaceutical and Dezhan Health were implicated in bribery involving hospital procurement officials, with Qianhong's agent providing 41,000 RMB in kickbacks [4]. Group 2: Regulatory Response - The NHSA has established a credit evaluation system for pricing and procurement to address the issues of inflated drug prices and corruption, aiming to protect patients and healthcare funds [5]. - The NHSA plans to guide local healthcare authorities in implementing trust ratings for companies involved in bribery and misconduct, enforcing measures to ensure compliance and safeguard healthcare funds [5].

Core Insights - Medtronic plc (NYSE:MDT) is recognized as a strong slow growth stock, with Truist Securities raising its price target to $110 from $103 while maintaining a Hold rating [1] - The company's fiscal second-quarter results showed significant revenue growth driven by its Pulsed Field Ablation (PFA) technology [1] Financial Performance - Medtronic's cardiac ablation solutions (CAS) division experienced a 71% year-over-year organic sales increase in the fiscal second quarter, attributed to the PFA technology [2] - In the last two fiscal quarters, CAS sales rose approximately 50% and 30%, indicating steady growth as PFA adoption continues [2] Strategic Investments - Truist noted an operating margin miss and a slight increase in earnings per share expectations despite revenue exceeding estimates, due to Medtronic's increased reinvestment ahead of major product launches [3] - This strategic investment is seen as limiting potential upside growth and profit acceleration [3] Company Overview - Medtronic is a leading name in medical technology, focusing on device-based therapeutics, with significant advancements in spine and minimally invasive treatments [4] - The company is recognized as a leader in robotic-assisted surgery technology [4]

Company Overview - Medtronic plc, based in Galway, Ireland, develops, manufactures, and sells device-based medical therapies, with a market cap of $134.7 billion [1] - The company's principal products address various medical conditions, including bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, pain management, and movement disorders [1] Market Position - Medtronic is classified as a large-cap stock, with a market cap exceeding $10 billion, highlighting its size and influence in the medical devices industry [2] - The company has a diverse geographic reach, with approximately half of its sales coming from international markets, which helps mitigate economic risks [2] Stock Performance - Medtronic shares reached a 52-week high of $106.33 recently, with a 13.9% gain over the past three months, outperforming the iShares U.S. Medical Devices ETF's (IHI) 3.4% gains [3] - Year-to-date, Medtronic shares have risen 31.5%, and over the past 52 weeks, they have climbed 22.6%, again outperforming IHI's YTD gains of 10.3% and 6% returns [4] Recent Financial Results - On November 18, Medtronic reported Q2 results, with an adjusted EPS of $1.36, exceeding Wall Street's expectations of $1.31, and revenue of $9 billion, surpassing the forecast of $8.9 billion [5] - The company anticipates full-year adjusted EPS in the range of $5.62 to $5.66 [5] Competitive Landscape - In comparison, Abbott Laboratories (ABT) has shown a YTD gain of 13.6% and a 9% increase over the past 52 weeks, indicating that Medtronic is outperforming its competitor in the medical devices sector [5]